Levobunolol Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Levobunolol
Therapeutic Class: Beta-Adrenergic Blocker
Subclass: Non-selective Beta-Adrenergic Receptor Antagonist (Ophthalmic)
Speciality: Ophthalmology
Schedule (India): H
Route(s): Ophthalmic (topical)
Formulations Available in India:
- Ophthalmic solution (eye drops): 0.25%, 0.5%
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Open-Angle Glaucoma
| Parameter | Recommendation |
| Starting dose | 1 drop of 0.5% solution into affected eye(s) once daily |
| Titration | If IOP reduction inadequate after 2–4 weeks, may increase to 1 drop twice daily |
| Usual maintenance dose | 1 drop once daily; 0.25% solution may be used for maintenance or in sensitive patients |
| Maximum dose | 1 drop twice daily (no additional benefit with more frequent dosing) |
Clinical notes:
- Onset of action: within 1 hour; peak effect at 2–6 hours
- Duration of action: up to 24 hours with 0.5% solution
- May be combined with prostaglandin analogues or carbonic anhydrase inhibitors
- Avoid concurrent use with other topical beta-blockers
- Advise punctal occlusion for 1–2 minutes after instillation to minimize systemic absorption
2. Ocular Hypertension
| Parameter | Recommendation |
| Starting dose | 1 drop of 0.5% solution into affected eye(s) once daily |
| Titration | May increase to twice daily if target IOP not achieved |
| Usual maintenance dose | 1 drop once daily |
| Maximum dose | 1 drop twice daily |
Clinical notes:
- IOP reduction typically 20–30% from baseline
- Reassess treatment response at 4 weeks before concluding inadequate efficacy
Secondary Indications – Adults (Off-label, if any)
Not applicable. No established off-label indications with strong evidence in Indian clinical practice.
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
⚠ Safety and efficacy not well established in children. Use only under paediatric ophthalmologist supervision.
Paediatric Glaucoma (Age ≥2 years)
| Parameter | Recommendation |
| Starting dose | 1 drop of 0.25% solution into affected eye(s) once daily |
| Titration | May increase to twice daily based on IOP response |
| Usual maintenance dose | 1 drop of 0.25% solution once or twice daily |
| Maximum dose | 1 drop twice daily |
Safety monitoring (mandatory):
- Monitor heart rate and respiratory status at each visit
- Watch for systemic beta-blockade signs: bradycardia, bronchospasm, lethargy, hypoglycaemia
- Punctal occlusion essential to minimize systemic absorption
- Parents should be counselled regarding warning signs
Age restriction: Not recommended below 2 years of age except under specialist supervision with close monitoring.
Secondary Indications – Paediatrics (Off-label, if any)
| Indication | Dose | Notes |
| Congenital glaucoma (adjunctive therapy) | 1 drop of 0.25% solution once or twice daily | OFF-LABEL; Specialist only; Adjunctive use pending definitive surgery; Limited case reports only; Timolol preferred as first-line beta-blocker per AIIMS paediatric protocols |
RENAL ADJUSTMENT
No dose adjustment required. Systemic absorption is minimal with proper ophthalmic administration technique (punctal occlusion).
HEPATIC ADJUSTMENT
| Hepatic Function | Recommendation |
| Mild impairment | No adjustment required with ophthalmic use |
| Moderate impairment | No adjustment required; monitor for systemic effects |
| Severe impairment | Use with caution; theoretical risk of accumulation if significant systemic absorption occurs; consider alternative antiglaucoma agents if systemic beta-blocking effects observed |
CONTRAINDICATIONS
- Bronchial asthma (current or history of)
- Severe chronic obstructive pulmonary disease (COPD)
- Sinus bradycardia (<50 bpm)
- Second-degree or third-degree atrioventricular block (without pacemaker)
- Sick sinus syndrome
- Cardiogenic shock
- Decompensated heart failure
- Hypersensitivity to levobunolol, other beta-blockers, or formulation components
- Concurrent intravenous verapamil or diltiazem administration
CAUTIONS
- Compensated heart failure: Use with close cardiac monitoring
- Diabetes mellitus: May mask hypoglycaemia warning signs (tachycardia, tremor)
- Thyrotoxicosis: May mask tachycardia and other clinical signs
- Myasthenia gravis: May exacerbate muscle weakness
- Peripheral vascular disease: May worsen symptoms
- Concurrent systemic beta-blockers: Additive cardiovascular and respiratory effects
- Corneal disease or dystrophy: May impair corneal healing
- Contact lens wearers: Contains benzalkonium chloride; advise lens removal before instillation and wait at least 15 minutes before reinsertion
- History of atopy or severe anaphylactic reactions: May increase reactivity to allergens
- Pheochromocytoma (untreated): Avoid unless alpha-blockade established
PREGNANCY
| Parameter | Recommendation |
| Overall safety | Use only if potential benefit justifies risk to fetus; systemic beta-blockers may cause fetal bradycardia, hypoglycaemia, and growth restriction |
| Preferred alternatives | Brimonidine (avoid near term), prostaglandin analogues (with obstetric consultation) |
| When may be used | If IOP control critical and alternatives unsuitable; preferably after first trimester |
| Monitoring | Fetal heart rate, intrauterine growth monitoring; neonatal observation for beta-blockade signs if used near delivery |
LACTATION
| Parameter | Recommendation |
| Compatibility | Likely compatible with breastfeeding; minimal systemic absorption expected with proper instillation technique |
| Preferred alternative | Timolol (more data available in lactation) |
| Expected milk levels | Low (minimal systemic absorption) |
| Infant monitoring | Feeding pattern, heart rate, respiratory status, alertness; monitor for bradycardia or lethargy (rare) |
ELDERLY
| Parameter | Recommendation |
| Starting dose | 1 drop of 0.25% solution once daily preferred in frail elderly |
| Titration | Gradual; assess tolerance before increasing frequency |
| Special considerations | Increased sensitivity to systemic beta-blocking effects; higher risk of bradycardia and orthostatic hypotension, especially if on concurrent oral antihypertensives or beta-blockers |
| Monitoring | Pulse rate and blood pressure at baseline and follow-up visits |
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect / Risk | Management |
| Systemic beta-blockers (atenolol, metoprolol, propranolol) | Additive cardiac depression; risk of severe bradycardia, hypotension, heart block | Avoid concurrent use or monitor closely with cardiology input |
| Verapamil / Diltiazem (IV or oral) | Severe bradycardia, AV block, cardiac arrest | Avoid concurrent use |
| Digitalis glycosides | Enhanced bradycardia risk | Monitor pulse; avoid if baseline bradycardia |
| Clonidine | Rebound hypertension if clonidine withdrawn abruptly | Discontinue beta-blocker several days before tapering clonidine |
| Class I antiarrhythmics (quinidine, disopyramide) | Additive negative inotropic effect | Avoid or use with extreme caution |
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect / Risk | Management |
| Insulin / Oral hypoglycaemics | May mask hypoglycaemia symptoms (tachycardia, tremor) | Counsel patient; monitor blood glucose more frequently |
| Amiodarone | Additive AV nodal conduction depression | Monitor ECG; watch for bradycardia |
| Other topical antiglaucoma agents (prostaglandins, CAIs) | Generally safe to combine | Space administration by at least 5 minutes |
| Adrenaline (topical ophthalmic) | Reduced efficacy of adrenaline; potential for mydriasis | Monitor response |
| Reserpine | Additive hypotension and bradycardia | Monitor BP and pulse |
COMMON ADVERSE EFFECTS
Ocular:
- Transient burning or stinging on instillation
- Ocular discomfort or irritation
- Blurred vision (transient)
- Conjunctival hyperaemia
- Dry eyes
- Photophobia
Systemic (due to absorption):
- Headache
- Dizziness
- Fatigue
SERIOUS ADVERSE EFFECTS
| Adverse Effect | Clinical Action |
| Severe bradycardia (<45 bpm) | Discontinue immediately; consider atropine if symptomatic |
| Bronchospasm | Discontinue immediately; administer bronchodilator; avoid future beta-blocker use |
| Heart block (second or third degree) | Discontinue; cardiology referral; pacing may be needed |
| Hypotension (symptomatic) | Discontinue; supportive care |
| Corneal anaesthesia / erosion | Discontinue; ophthalmology review |
| Exacerbation of myasthenia gravis | Discontinue; neurology input |
| Severe allergic reactions | Discontinue permanently |
MONITORING REQUIREMENTS
| Phase | Parameters |
|
Baseline
|
IOP measurement, visual acuity, visual field assessment (if indicated), optic disc evaluation, pulse rate, blood pressure (especially if cardiovascular comorbidities) |
|
After initiation
|
IOP recheck at 2–4 weeks; pulse and BP assessment |
|
Long-term
|
IOP every 3–6 months; visual field assessment annually or as indicated; pulse and BP monitoring at each visit if prolonged use or comorbid cardiovascular/respiratory disease |
BRANDS AVAILABLE IN INDIA
- Betagan® Eye Drops
- Levobunolol Eye Drops (generic)
Note: Limited brand availability in India compared to timolol. Verify current availability with local distributors.
PRICE RANGE (INR)
| Formulation | Approximate Price |
| 0.5% eye drops (5 mL) | ₹80–₹150 |
| 0.25% eye drops (5 mL) | ₹60–₹120 |
- Not under NPPA price control
- Available through private retail; limited government hospital supply
- Prices vary by brand and region
CLINICAL PEARLS
- Once-daily advantage: Levobunolol 0.5% has longer duration of action (up to 24 hours) compared to timolol, allowing effective once-daily dosing for better compliance.
- Punctal occlusion is essential: Advise patients to apply gentle pressure over the nasolacrimal duct for 1–2 minutes after instillation to minimize systemic absorption and reduce cardiovascular/respiratory side effects.
- Non-selective agent: Unlike betaxolol, levobunolol blocks both β1 and β2 receptors; avoid in patients with asthma or significant COPD. Betaxolol is preferred in such cases.
- Diabetic patients: Counsel regarding masked hypoglycaemia symptoms; sweating remains a reliable warning sign.
- Contact lens wearers: Benzalkonium chloride preservative may be absorbed by soft contact lenses; advise removal before instillation and reinsertion after 15 minutes.
- Unilateral treatment: Monitor contralateral eye for crossover IOP reduction due to systemic absorption; may affect clinical trial assessments.
TAGS
Levobunolol; glaucoma; ocular-hypertension; beta-blocker; ophthalmic; antiglaucoma; non-selective; IOP-lowering; Schedule-H; pregnancy-caution
VERSION
RxIndia v1.0 — 14 Feb 2026
REFERENCES
- CDSCO Product Database and Approved Drug Labels
- Indian Pharmacopoeia (IP)
- National Formulary of India (NFI)
- AIIMS Glaucoma Management Protocols
- API Textbook of Medicine (Ophthalmology chapter)
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics (pharmacology reference)
- ICMR Standard Treatment Guidelines (Ophthalmology)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.